Cat. No.: HY-N0892

AKBA

(Synonyms: Acetyl-11-keto-β-boswellic acid)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 67416-61-9
Formula: C₃₂H₄₈O₅
Molecular Weight:512.72

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AKBA Chemical Structure

CAS No.: 67416-61-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
Purity & Documentation
Help & FAQs
Classifications
Bioz

Biological Activity

Description

AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

All HIF/HIF Prolyl-Hydroxylase Isoforms :

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A253 cell line	IC₅₀	16.9 μM Compound: 4, (beta-AKBA)	Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 25618017]
A2780	IC₅₀	14.1 μM Compound: 4, (beta-AKBA)	Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 25618017]
A549	IC₅₀	3 μM Compound: 4	Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	[PMID: 24844534]
DLD-1	IC₅₀	20.9 μM Compound: 4, (beta-AKBA)	Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 25618017]
HCT-8	IC₅₀	17.5 μM Compound: 4, (beta-AKBA)	Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 25618017]
HeLa	IC₅₀	31 μM Compound: 4, AKBA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21334793]
HL-60	IC₅₀	11 μM Compound: 4, AKBA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21334793]
HT-29	IC₅₀	19.4 μM Compound: 4, (beta-AKBA)	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 25618017]
HUVEC	IC₅₀	7.45 μM Compound: 1, AKBA	Antiproliferation activity against HUVEC cells after 48 hrs by CCK-8 assay Antiproliferation activity against HUVEC cells after 48 hrs by CCK-8 assay	[PMID: 25819335]
LNCaP	GI₅₀	27.43 μM Compound: AKBA	Anti-proliferative activity against human LNCAP cells measured after 96 hrs by MTT assay Anti-proliferative activity against human LNCAP cells measured after 96 hrs by MTT assay	[PMID: 27997878]
PC-3	GI₅₀	31.86 μM Compound: AKBA	Anti-proliferative activity against human PC3 cells measured after 96 hrs by MTT assay Anti-proliferative activity against human PC3 cells measured after 96 hrs by MTT assay	[PMID: 27997878]
PC-3	GI₅₀	31.9 μM Compound: 1; AKBA	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 30153964]
RAW264.7	IC₅₀	15.6 μM Compound: AKBA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs	[PMID: 23391590]
Sf21	IC₅₀	>40 μM Compound: 29	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]

In Vitro

AKBA (Acetyl-11-keto-β-boswellic acid) significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in brain tissues in middle cerebral artery occlusion (MCAO) rats at 48 hours post reperfusion. In primary cultured neurons, AKBA increased the Nrf2 and HO-1 expression, which provided protection against OGD-induced oxidative insult. Additionally, AKBA treatment increased Nrf2 binding activity to antioxidant-response elements (ARE)^[1].
AKBA (Acetyl-11-keto-β-boswellic acid) significantly inhibited human colon adenocarcinoma growth, showing arrest of the cell cycle in G1-phase and induction of apoptosis^[3].
AKBA (Acetyl-11-keto-β-boswellic acid) triggered significant lipolysis in 3T3-L1 adipocytes as shown by reduced neutral lipids in cytosol and increased free fatty acids in culture medium. Increased lipolysis by AKBA was accompanied by up-regulation of lipolytic enzymes, adipocyte triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), and a decreased expression of lipid droplet stability regulator perilipin. In addition, AKBA (Acetyl-11-keto-β-boswellic acid) treatment reduced phenotypic markers of mature adipocyte aP2, adiponectin and glut-4 in mature adipocytes^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AKBA (Acetyl-11-keto-β-boswellic acid) significantly prevented the formation of intestinal adenomatous polyps without toxicity to mice. AKBA's activity both in the prevention of small intestinal and colonic polyps was more potently than aspirin. Histopathologic examination revealed that AKBA's effect, that is the reduction of polyp size and degree of dysplasia, was more prominent in larger sized polyps, especially those originating in colon^[1].
AKBA (Acetyl-11-keto-β-boswellic acid) administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity. The activity of AKBA was more potent than that of aspirin^[3].
AKBA (Acetyl-11-keto-β-boswellic acid) exhibited anti-cancer activity in vitro and in vivo. With oral application in mice, AKBA significantly inhibited SGC-7901 and MKN-45 xenografts without toxicity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 67416-61-9
Appearance Solid
Molecular Weight 512.72
Formula C₃₂H₄₈O₅
Color White to off-white
SMILES

C[C@@]([C@@](C1=C2)(CC[C@@](C)(CC[C@H]3C)[C@@]1([H])[C@H]3C)C)(CC[C@@]4([H])[C@@]5(C)C(O)=O)[C@@](C2=O)([H])[C@]4(CC[C@H]5OC(C)=O)C
Synonyms

Acetyl-11-keto-β-boswellic acid
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All Cell Proliferation/Viability AssayIFCell Imaging/StainingWB2D/3D Cell Culture and Differentiation

Sort by:

Journal Impact Factor

Phytomedicine

Xihuang Pill ameliorates the immune microenvironment of TNBC by activation of AMPKα-ACC signaling-mediated lipid metabolic reprogramming. [Abstract]

2026 Jul 25:157:158311. PMID: 42172981

AKBA purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jul 25:157:158311. [Abstract]

AKBA (0-40 μM; 48 h) inhibited cell viability in 4T1 cells.

AKBA purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jul 25:157:158311. [Abstract]

AKBA (30 μM; 48 h) reduced PC content in 4T1 cells.

AKBA purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jul 25:157:158311. [Abstract]

AKBA (0, 15, 30 μM; 24 h) activated the AMPKα-ACC signaling pathway in 4T1 cells.
Int Immunopharmacol

Acetyl-11-keto-β-boswellia acid attenuates Ti particle-induced osteoblastic oxidative stress and osteolysis through the Foxo3 signaling pathway. [Abstract]

2024 Nov 6;143(Pt 3):113547. PMID: 39510032

AKBA purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 6;143(Pt 3):113547. [Abstract]

AKBA (0, 0.1, 1, 10, 20, 50 μM; 24 h) showed no significant effect on cell viability in osteoblasts.

AKBA purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 6;143(Pt 3):113547. [Abstract]

AKBA (0, 0.1, 1, 10, 20, 50 μM; 24 h) and 200 μM H2O2 and 0.1 mg/ml Ti particles were added for 24 h, the ROS level was the highest in the simple injury group. With an increasing AKBA concentration, the ROS levels in the cells gradually decreased. At a concentration of 10 μM, the ROS levels significantly decreased.

AKBA purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 6;143(Pt 3):113547. [Abstract]

AKBA (0, 1, 10, 50 μM; 24 h) showed the expression level of NADPH oxidase (Nox4) and cleaved caspase-3 and Caspase3in osteoblasts significantly decreased. The expression level of catalase reductase (Prdx3) first increased but then decreased, peaking at a concentration of 10 μM. The expression level of the apoptosis suppressor protein (Bcl2) was increased, and its expression level was the highest when the AKBA concentration was 10 μM.

AKBA purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 6;143(Pt 3):113547. [Abstract]

AKBA (0, 1, 10, 50 μM; 7 days) promoted the osteogenic differentiation of BMSCs.

AKBA purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Nov 6;143(Pt 3):113547. [Abstract]

AKBA (0, 1, 10, 50 μM; 21 days) alleviated the inhibition of BMSCs mineralization mediated by Ti particles and hydrogen peroxide.
Int Immunopharmacol

AKBA alleviates experimental pancreatitis by inhibiting oxidative stress in Macrophages through the Nrf2/HO-1 pathway. [Abstract]

2023 Aug:121:110501. PMID: 37364326
Sci Rep

Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS. [Abstract]

2025 Apr 30;15(1):15207. PMID: 40307322

Solvent & Solubility

In Vitro:

DMSO : ≥ 5.2 mg/mL (10.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9504 mL

9.7519 mL

19.5038 mL

5 mM

0.3901 mL

1.9504 mL

3.9008 mL

10 mM

0.1950 mL

0.9752 mL

1.9504 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (252 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9504 mL	9.7519 mL	19.5038 mL	48.7596 mL
	5 mM	0.3901 mL	1.9504 mL	3.9008 mL	9.7519 mL
	10 mM	0.1950 mL	0.9752 mL	1.9504 mL	4.8760 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

AKBA

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) AKBA

All HIF/HIF Prolyl-Hydroxylase Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

Help & FAQs

Complete Stock Solution Preparation Table

AKBA Related Classifications

HY-N0892 Related Classifications